Allouche Cyril 4
4 · Revance Therapeutics, Inc. · Filed Nov 9, 2018
Insider Transaction Report
Form 4
Allouche Cyril
Principal Financial Officer
Transactions
- Sale
Common Stock
2018-11-09$23.72/sh−2,188$51,899→ 4,750 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2018-11-09−2,188→ 7,500 totalExercise: $13.35Exp: 2026-10-30→ Common Stock (2,188 underlying) - Exercise/Conversion
Common Stock
2018-11-09$13.35/sh+2,188$29,210→ 6,938 total
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mr. Allouche.
- [F2]The Option vests in accordance to the following schedule: 25% on the first anniversary of the vesting commencement date of October 31, 2016, and 1/48th vesting each month thereafter for the remaining three years, subject to Mr. Allouche's Continuous Service (as defined in the Plan) as of such date.